Page 244 - பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Study shows reliability and robustness of injectable anti-obesity medication A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the Journal of the American Medical Association. The 68-week study was conducted at 41 sites in the United States from August 2018 to April 2020 and was designed to boost total weight loss with semaglutide by combining the medication with a more intensive diet and physical activity program than what was used in the STEP 1 trial, published online February 10th in the

United statesThomas waddenW timothy garveyEmily hendersonDepartment of nutrition sciencesDrug administrationDepartment of psychiatryPerelman school of medicineUniversity of alabama at birminghamJournal of the american medical associationUniversity of pennsylvaniaAmerican medicalNew england journalPerelman schoolNutrition sciencesWeight loss